NCT02971501 2026-03-17
Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain Metastases
National Cancer Institute (NCI)
Phase 2 Active not recruiting
National Cancer Institute (NCI)
Shanghai Chest Hospital
Second Affiliated Hospital of Nanchang University
Genentech, Inc.
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.